NeurologyLive® Friday 5 — September 18, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!

Click the read more or watch now buttons for more details and information about each highlight.

1: Brain Network Changes Appear Decades Before Motor Symptoms in Huntington Disease

In a recent Q&A interview, Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.

2: Previewing Advancements in Hypersomnia Diagnosis and Treatment

In a recent Q&A interview, KuangHua Guo, MD, PhD, a sleep medicine specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.

3: Zilganersen FAQs: What Clinicians Should Know About the First Approved Treatment for Alexander Disease

In a recent Q&A interview, Amy Waldman, MD, associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, talked about FAQs on the first FDA-approved treatment for Alexander disease, zilganersen (Zanvastro).

4: NeuroVoices: Robert Bowser, PhD, on TDP-43’s Role in ALS

In our latest NeuroVoices, Robert Bowser, PhD, the chief scientific officer at Barrow Neurological Institute, recapped his presentation on TDP-43 biology, presented at the 2026 ALS Nexus Conference, held August 23-26, in Orlando, Florida.

5: What's New in Stroke Rehabilitation and Recovery: An FAQ on the AHA/ASA Guideline

In a recent Q&A interview, Lorie G. Richards, PhD, OTR/L, associate professor in the Department of Occupational and Recreational Therapies at the University of Utah, talked about FAQs on the AHA’s and ASA’s "2026 Guideline for Adult Stroke Rehabilitation and Recovery,” replacing their 2016 stroke rehabilitation guideline.